- Home
- BXSL vs LEGN Comparison
BXSL vs LEGN Comparison
Compare BXSL & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BXSL
- LEGN
- Stock Information
- Founded
- BXSL 2018
- LEGN 2014
- Country
- BXSL United States
- LEGN United States
- Employees
- BXSL N/A
- LEGN N/A
- Industry
- BXSL Trusts Except Educational Religious and Charitable
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- BXSL Finance
- LEGN Health Care
- Exchange
- BXSL Nasdaq
- LEGN Nasdaq
- Market Cap
- BXSL 7.5B
- LEGN 7.0B
- IPO Year
- BXSL N/A
- LEGN 2020
- Fundamental
- Price
- BXSL $31.65
- LEGN $27.78
- Analyst Decision
- BXSL Buy
- LEGN Strong Buy
- Analyst Count
- BXSL 6
- LEGN 13
- Target Price
- BXSL $31.38
- LEGN $75.67
- AVG Volume (30 Days)
- BXSL 964.2K
- LEGN 1.5M
- Earning Date
- BXSL 05-07-2025
- LEGN 05-13-2025
- Dividend Yield
- BXSL 9.73%
- LEGN N/A
- EPS Growth
- BXSL N/A
- LEGN N/A
- EPS
- BXSL 3.14
- LEGN N/A
- Revenue
- BXSL $1,380,706,000.00
- LEGN $728,303,000.00
- Revenue This Year
- BXSL $12.37
- LEGN $65.96
- Revenue Next Year
- BXSL $8.12
- LEGN $52.55
- P/E Ratio
- BXSL $10.08
- LEGN N/A
- Revenue Growth
- BXSL 16.76
- LEGN 112.46
- 52 Week Low
- BXSL $25.89
- LEGN $29.27
- 52 Week High
- BXSL $34.64
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- BXSL 64.90
- LEGN 29.61
- Support Level
- BXSL $29.07
- LEGN $30.25
- Resistance Level
- BXSL $30.04
- LEGN $33.30
- Average True Range (ATR)
- BXSL 0.52
- LEGN 1.78
- MACD
- BXSL 0.34
- LEGN -0.57
- Stochastic Oscillator
- BXSL 98.20
- LEGN 5.19
About BXSL Blackstone Secured Lending Fund of Beneficial Interest
Blackstone Secured Lending Fund is a non-diversified, closed-end management investment company. The investment objectives of the company are to generate current income and, to a lesser extent, long-term capital appreciation. The company seeks to achieve its investment objectives by investing in originated loans and other securities, including syndicated loans of private U.S. companies, typically in the form of first lien senior secured and unitranche loans, unsecured and subordinated loans, and other securities.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.